SOURCE: Daxor Corp.

Daxor Corp.

November 03, 2014 08:30 ET

Daxor Announces Publication of a Study Comparing Two Widely Used Surrogate Tests for Estimating Blood Volume With Direct Measurement of Blood Volume

NEW YORK, NY--(Marketwired - Nov 3, 2014) - Daxor Corporation (NYSE MKT: DXR) -- The study (Brain-type natruretic peptide and right ventricular end-diastolic volume index measurements in imprecise estimates of circulating blood volume in critically ill subjects. J Trauma Acute Care Surg, Volume 75, Number 5) involved 81 subjects; 42% of the subjects had septic shock/severe sepsis. The mortality rate of this group was 17%. The conclusion of the study proved that right ventricular end-diastolic volume index (RVEDVI) and brain-type natriuretic peptide (BNP) measurements "did not correlate with blood volume status as determined by the BVA-100 Analyzer in critically ill surgical patients in whom pulmonary artery catheterization (PAC) insertion was used to guide treatment. These results suggest that RVEDVI and BNP, in common use clinically, are not precise indices of intravascular volume status, although these parameters may reflect cardiac preload". "The importance of this study is that clinicians must be cognizant of the limitations of currently available modalities that are being used in clinical decision making to optimize volume loading". The study further indicates that "directly measuring circulating blood volume (BV) may provide valuable insight into intravascular volume status, while at the same time furnishing a practical means to judiciously guide fluid management" and that "technologic innovations have made BV measurements in real time more feasible and useful with the development of the semi-automated, Food and Drug Administration-approved BVA-100 Blood Volume Analyzer" manufactured by the Daxor Corporation.

Dr. Joseph Feldschuh, President and CEO of the Daxor Corporation, said, "Tens of thousands of patients are treated every year in intensive care units using tests such as BNP and RVEDVI to estimate blood volume. This study, by Dr. Mihae Yu and colleagues demonstrates decisively that such surrogate substitute tests are inaccurate. When using the BVA-100 Blood Volume Analyzer, it is possible to measure blood volume to within 98% accuracy. 

Blood volume derangements are present in the majority of cases of patients ill enough to be admitted to an intensive care unit. Septic patients who may be infected with a bacteria or virus are especially susceptible to a collapse of their circulating blood volume. If this condition is not rapidly recognized and correctly treated, patients may develop kidney failure leading to multi-organ failure and death. 

A previous study from The Queen's Medical Center (A Prospective Randomized Trial Using Blood Volume Analysis in Addition to Pulmonary Artery Catheter, Compared with Pulmonary Artery Catheter Alone, to Guide Shock Resuscitation in Critically Ill Surgical Patients, Shock, Vol 35, No. 3, pp. 220-228, 2011)involving 100 patients demonstrated that half the patients whose management included blood volume measurement for treatment had an 8% death rate vs. a 24% death rate for those who were treated without this vital measurement. Blood volume measurement can be completed in under an hour with preliminary results available within 30 minutes."

Daxor Corporation, (NYSE MKT: DXR) is the manufacturer of the BVA-100 Blood Volume Analyzer, the only FDA approved semi-automated blood volume analyzer.

Contact Information

  • Contact Information:
    Daxor Corporation:
    Diane Meegan
    212-330-8512
    (Investor Relations)
    dmeegan@daxor.com

    Richard Dunn
    212-330-8502
    (Director of Operations)
    rdunn@daxor.com